Executive SummaryWill submit an IND to the FDA for a "unique" oral contraceptive by year-end. The firm says that this contraceptive will reduce the risk of pregnancy should a woman forget to take a pill and eliminate breakthrough bleeding and spotting that can occur with use of low-dose oral contraceptives. A pilot study of the product will begin in the first quarter of 1989.
You may also be interested in...
Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further.
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.